These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

742 related items for PubMed ID: 20235539

  • 1. An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs.
    Perola E.
    J Med Chem; 2010 Apr 08; 53(7):2986-97. PubMed ID: 20235539
    [Abstract] [Full Text] [Related]

  • 2. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA.
    Chem Res Toxicol; 2011 Sep 19; 24(9):1420-56. PubMed ID: 21790149
    [Abstract] [Full Text] [Related]

  • 3. Understanding and predicting druggability. A high-throughput method for detection of drug binding sites.
    Schmidtke P, Barril X.
    J Med Chem; 2010 Aug 12; 53(15):5858-67. PubMed ID: 20684613
    [Abstract] [Full Text] [Related]

  • 4. Drug-like density: a method of quantifying the "bindability" of a protein target based on a very large set of pockets and drug-like ligands from the Protein Data Bank.
    Sheridan RP, Maiorov VN, Holloway MK, Cornell WD, Gao YD.
    J Chem Inf Model; 2010 Nov 22; 50(11):2029-40. PubMed ID: 20977231
    [Abstract] [Full Text] [Related]

  • 5. Pharmacophore modeling and applications in drug discovery: challenges and recent advances.
    Yang SY.
    Drug Discov Today; 2010 Jun 22; 15(11-12):444-50. PubMed ID: 20362693
    [Abstract] [Full Text] [Related]

  • 6. Do biologically relevant compounds have more chance to be drugs?
    Kong DX, Ren W, Lü W, Zhang HY.
    J Chem Inf Model; 2009 Oct 22; 49(10):2376-81. PubMed ID: 19852515
    [Abstract] [Full Text] [Related]

  • 7. In silico identification of bioisosteric functional groups.
    Ertl P.
    Curr Opin Drug Discov Devel; 2007 May 22; 10(3):281-8. PubMed ID: 17554854
    [Abstract] [Full Text] [Related]

  • 8. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE, Chen I, Davis B.
    Curr Opin Drug Discov Devel; 2007 May 22; 10(3):289-97. PubMed ID: 17554855
    [Abstract] [Full Text] [Related]

  • 9. Quo vadis, virtual screening? A comprehensive survey of prospective applications.
    Ripphausen P, Nisius B, Peltason L, Bajorath J.
    J Med Chem; 2010 Dec 23; 53(24):8461-7. PubMed ID: 20929257
    [No Abstract] [Full Text] [Related]

  • 10. The importance of drug-target residence time.
    Zhang R, Monsma F.
    Curr Opin Drug Discov Devel; 2009 Jul 23; 12(4):488-96. PubMed ID: 19562645
    [Abstract] [Full Text] [Related]

  • 11. Capturing structure-activity relationships from chemogenomic spaces.
    Wendt B, Uhrig U, Bös F.
    J Chem Inf Model; 2011 Apr 25; 51(4):843-51. PubMed ID: 21410249
    [Abstract] [Full Text] [Related]

  • 12. Scaffold distributions in bioactive molecules, clinical trials compounds, and drugs.
    Hu Y, Bajorath J.
    ChemMedChem; 2010 Feb 01; 5(2):187-90. PubMed ID: 20014088
    [No Abstract] [Full Text] [Related]

  • 13. Lead optimization via high-throughput molecular docking.
    Joseph-McCarthy D, Baber JC, Feyfant E, Thompson DC, Humblet C.
    Curr Opin Drug Discov Devel; 2007 May 01; 10(3):264-74. PubMed ID: 17554852
    [Abstract] [Full Text] [Related]

  • 14. Drug and drug candidate building block analysis.
    Wang J, Hou T.
    J Chem Inf Model; 2010 Jan 01; 50(1):55-67. PubMed ID: 20020714
    [Abstract] [Full Text] [Related]

  • 15. The properties of known drugs. 1. Molecular frameworks.
    Bemis GW, Murcko MA.
    J Med Chem; 1996 Jul 19; 39(15):2887-93. PubMed ID: 8709122
    [Abstract] [Full Text] [Related]

  • 16. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.
    Bender A, Scheiber J, Glick M, Davies JW, Azzaoui K, Hamon J, Urban L, Whitebread S, Jenkins JL.
    ChemMedChem; 2007 Jun 19; 2(6):861-73. PubMed ID: 17477341
    [Abstract] [Full Text] [Related]

  • 17. Alternative variables in drug discovery: promises and challenges.
    Abad-Zapatero C, Champness EJ, Segall MD.
    Future Med Chem; 2014 Apr 19; 6(5):577-93. PubMed ID: 24649959
    [Abstract] [Full Text] [Related]

  • 18. Utility of protein structures in overcoming ADMET-related issues of drug-like compounds.
    Stoll F, Göller AH, Hillisch A.
    Drug Discov Today; 2011 Jun 19; 16(11-12):530-8. PubMed ID: 21554979
    [Abstract] [Full Text] [Related]

  • 19. Ligand efficiency indices as guideposts for drug discovery.
    Abad-Zapatero C, Metz JT.
    Drug Discov Today; 2005 Apr 01; 10(7):464-9. PubMed ID: 15809192
    [No Abstract] [Full Text] [Related]

  • 20. Drugs in other drugs: a new look at drugs as fragments.
    Siegel MG, Vieth M.
    Drug Discov Today; 2007 Jan 01; 12(1-2):71-9. PubMed ID: 17198975
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.